Transformative Pharmaceutical Solutions, LLC

tpsglobal.com

Publicis Touchpoint Solutions (Touchpoint) designs and implements customized healthcare sales, service, and communications teams. We listen to our clients and create cross-channel solutions that achieve their goals.

Related News

PAOG ANNOUNCES CEO INTERVIEW DISCUSSING CANNABIS INVESTIGATIONAL NEW DRUG APPLICATION PLANS WITH FDA

PAO Group, Inc | October 05, 2020

news image

PAO Group, Inc. today announced an interview of CEO Jim DiPrima on MoneyTV where Mr. DiPrima discusses recent news regarding PAOG's latest moves to engage a contract research organization (CRO) to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA). MoneyTV is the internationally syndicated television program all about money and what makes it happen, featuring informative interviews with company CEOs and executives, providing insights into their ...

Read More

BUSINESS INSIGHTS

INTEGRITY BIO AND LAKEPHARMA BECOME CURIA

Curia | February 15, 2022

news image

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, announced that Integrity Bio and LakePharma, two companies that it acquired last year, have fully transitioned to the Curia brand. This change reflects the accelerated organizational integration of the acquired companies into Curia and its provision of comprehensive biologics discovery, development and manufacturing solutions to customers. Curia completed the acquisition of Integrity Bio in August 2021...

Read More

GENSCRIPT LAUNCHES NEOANTIGEN SPECIFIC PEPTIDE SYNTHESIS SERVICE FOR PRECISION IMMUNO-ONCOLOGY THERAPEUTIC DEVELOPMENT

BioSpace: Biotech, | April 01, 2020

news image

GenScript USA Inc., a world leading biotechnology company, today announced the commercial launch of its neoantigen peptide synthesis service for biotech and pharma companies developing personalized cancer therapeutics. The service builds on GenScript's work over the past year producing 2,500 highly difficult neoantigen peptides for more than 50 of the world's leading immuno-oncology companies. Unlike traditional targets such as tumor-associated antigens, neoantigens are novel peptides on...

Read More

PHARMACY MARKET

JUBILANT HOLLISTERSTIER LLC ENTERS INTO COOPERATIVE AGREEMENT OF $149.6 MN WITH US GOVERNMENT TO EXPAND CRITICAL VACCINE MANUFACTURING CAPACITY

Jubilant Pharmova Limited | May 31, 2022

news image

Jubilant Pharmova Limited has announced today that Jubilant Pharma Limited, a wholly owned subsidiary of the Company, through one of its wholly owned subsidiaries, Jubilant HollisterStier LLC, (JHS) a leading US-based pharmaceutical contract manufacturer has entered into a cooperative agreement for $149.6 million (USD) with the Army Contracting Command, in coordination with the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) on behalf of th...

Read More
news image

PAOG ANNOUNCES CEO INTERVIEW DISCUSSING CANNABIS INVESTIGATIONAL NEW DRUG APPLICATION PLANS WITH FDA

PAO Group, Inc | October 05, 2020

PAO Group, Inc. today announced an interview of CEO Jim DiPrima on MoneyTV where Mr. DiPrima discusses recent news regarding PAOG's latest moves to engage a contract research organization (CRO) to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA). MoneyTV is the internationally syndicated television program all about money and what makes it happen, featuring informative interviews with company CEOs and executives, providing insights into their ...

Read More
news image

BUSINESS INSIGHTS

INTEGRITY BIO AND LAKEPHARMA BECOME CURIA

Curia | February 15, 2022

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, announced that Integrity Bio and LakePharma, two companies that it acquired last year, have fully transitioned to the Curia brand. This change reflects the accelerated organizational integration of the acquired companies into Curia and its provision of comprehensive biologics discovery, development and manufacturing solutions to customers. Curia completed the acquisition of Integrity Bio in August 2021...

Read More
news image

GENSCRIPT LAUNCHES NEOANTIGEN SPECIFIC PEPTIDE SYNTHESIS SERVICE FOR PRECISION IMMUNO-ONCOLOGY THERAPEUTIC DEVELOPMENT

BioSpace: Biotech, | April 01, 2020

GenScript USA Inc., a world leading biotechnology company, today announced the commercial launch of its neoantigen peptide synthesis service for biotech and pharma companies developing personalized cancer therapeutics. The service builds on GenScript's work over the past year producing 2,500 highly difficult neoantigen peptides for more than 50 of the world's leading immuno-oncology companies. Unlike traditional targets such as tumor-associated antigens, neoantigens are novel peptides on...

Read More
news image

PHARMACY MARKET

JUBILANT HOLLISTERSTIER LLC ENTERS INTO COOPERATIVE AGREEMENT OF $149.6 MN WITH US GOVERNMENT TO EXPAND CRITICAL VACCINE MANUFACTURING CAPACITY

Jubilant Pharmova Limited | May 31, 2022

Jubilant Pharmova Limited has announced today that Jubilant Pharma Limited, a wholly owned subsidiary of the Company, through one of its wholly owned subsidiaries, Jubilant HollisterStier LLC, (JHS) a leading US-based pharmaceutical contract manufacturer has entered into a cooperative agreement for $149.6 million (USD) with the Army Contracting Command, in coordination with the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) on behalf of th...

Read More